纳米化疗药物对胆管癌细胞中Survivin和p53表达的调节  

Expression of Survivin and p53 in human biliary tract carcinoma cell line regulated by nanochemotherapy drug

作　　者：苏瑛[1] 汪昕[1] 唐滔[1] 陈波[1] 郑建伟[1] 李宏[1] 邹声泉[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院普外科,武汉430030

出　　处：《中国医师进修杂志（外科版）》2008年第5期12-15,共4页Chinese Journal of Postgraduates of Medicine

基　　金：国家高技术发展研究计划（863计划）项目（2002AA214061）

摘　　要：目的通过检测纳米化疗药物干预人胆管癌细胞侏QBC939中Survivin和p53表达变化的情况，探讨其抑制肿瘤的机制。方法体外培养人胆管癌细胞诛QBC939，随机分成5组，即空白对照组、纳米药囊组、有磁无药组、5－Fu组和吉西他滨（健择）组。采用MTT法和流式细胞术检测各组在药物干预后的细胞生长状态，并通过反转录－聚合酶链反应（RT—PCR）和Weslern blot检测各组中Survivin和p53mRNA和蛋白的表达情况。结果空白对照组、有磁无药组、5－FU组、健择组、纳米药囊组中Survivin mRNA和蛋白表达依次降低，p53N则相反；纳米药囊组对QBC939细胞生长抑制明显，细胞凋亡率较其他各组高（除健择组）。上述结果差异均有统计学意义（P〈0．05）。结论纳米化疗药物对人胆管癌细胞株QBC939有明湿抑制作用，下调Survivin和上调p53可能是其抑瘤机制之一。Objective To determine the effect of nanoehemotherapy drug on Survivin mad p53 expressed by human biliary tract carcinoma cell line QBC939. Methods Culturing the human biliary tract carcinoma ceil line QBC939 in vitro and it was divided into five groups including saline, nanoehemotherapy drug, nanoparticle without nanochemotherapy drug, 5-FU and gemcitabine. Using the methods of MTT and flow cytometry to observe the growth of QBC939 which was dealt with different drugs. In addition, RT-PCR and Western blot were used to detect the expression of mRNA and protein by Survivin or p53. Results The expression of mRNA and protein by Survivin decreased in the following set： saline, nanoparticle without nanoehemotherapy drug, 5-FU, gemcitabine and nanochemotherapy drug, respectively. However, the expression of mRNA and protein by p53 were in reverse order.The inhibiting action to QBC939 was obvious in nanoehemotherapy drng and the apoptotic rate was higher than others except for gemcitabine （P 〈 0.05 ） . Conclusion Nanoehemotherapy drug has significant effect on treatment cholangiocarcinoma in vitro, which may attribute to the down regulation of Survivin and up regnlation of p53.

关 键 词：纳米技术 基因 p53 SURVIVIN 化疗药物 

分 类 号：R735.7[医药卫生—肿瘤] R394.2[医药卫生—临床医学]